Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 13/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035018 | 0.84 | TAAR1 (0.30) | TAAR1 | |
| SCHEMBL18726461 | 0.84 | LIPG (0.36) | TAAR1HTR1A | |
| SCHEMBL13082167 | 0.84 | FOLH1 (0.47) | TAAR1HTR2AIDO1 | |
| SCHEMBL15810525 | 0.84 | TDP1 (0.44) | TAAR1HSPA5 | |
| SCHEMBL13094281 | 0.84 | TAAR1 (0.56) | TAAR1HTR2A | |
| SCHEMBL20228542 | 0.80 | — | — | |
| SCHEMBL10062411 | 0.79 | — | — | |
| SCHEMBL13772838 | 0.77 | — | — | |
| SCHEMBL20346318 | 0.77 | — | — | |
| SCHEMBL12016048 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220176363-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10702861-B2 | Process for oligomerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200030783-A1 | PROCESS FOR OLIGOMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338542-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | TAAR1 1180/4885HSPA5 3144/4885HTR1A 568/4885 |
| US-20200030783-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | TAAR1 1180/4885HSPA5 3144/4885HTR1A 568/4885 |
| US-20220176363-A1 | PROCESS FOR OLIGOMERIZATION | OXER1, NOD1, LIG1 | TAAR1 1180/4885HSPA5 3144/4885HTR1A 568/4885 |
| US-10702861-B2 | Process for oligomerization | OXER1, NOD1, LIG1 | TAAR1 1180/4885HSPA5 3144/4885HTR1A 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.